Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
8. lappuse
... oral use ; condi- tions for marketing . 310.501 Patient package inserts for oral con- traceptives . 310.502 Certain drugs accorded new drug sta- tus through rulemaking procedures . 310.503 Requirements regarding certain ra- dioactive ...
... oral use ; condi- tions for marketing . 310.501 Patient package inserts for oral con- traceptives . 310.502 Certain drugs accorded new drug sta- tus through rulemaking procedures . 310.503 Requirements regarding certain ra- dioactive ...
14. lappuse
... oral use in self - medication , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sodium gentisate and all other components of the preparation meet their ...
... oral use in self - medication , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sodium gentisate and all other components of the preparation meet their ...
17. lappuse
... oral use in self - medication , and con- taining no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The carbetapentane citrate and all other components of the prepara- tion meet ...
... oral use in self - medication , and con- taining no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The carbetapentane citrate and all other components of the prepara- tion meet ...
24. lappuse
... oral use ; conditions for marketing . ( a ) Studies have shown evidence of clinically significant differences in bio- availability in different batches of cer- tain marketed digoxin products for oral use from single manufacturers as ...
... oral use ; conditions for marketing . ( a ) Studies have shown evidence of clinically significant differences in bio- availability in different batches of cer- tain marketed digoxin products for oral use from single manufacturers as ...
25. lappuse
... oral use . The Commissioner is of the opinion that digoxin products for oral use are new drugs within the meaning of section 201 ( p ) of the Federal Food , Drug , and Cosmetic Act for which approved new drug applications are required ...
... oral use . The Commissioner is of the opinion that digoxin products for oral use are new drugs within the meaning of section 201 ( p ) of the Federal Food , Drug , and Cosmetic Act for which approved new drug applications are required ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning